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Abstract 64 
We performed a genome-wide association study of total hip replacements, based on variants 65 
identified through whole-genome sequencing, which included 4,657 Icelandic patients and 66 
207,514 population controls. We discovered two rare signals that strongly associate with 67 
osteoarthritis total hip replacement; a missense mutation, c.1141G>C (p.Asp369His), in the 68 
COMP gene (allelic frequency = 0.026%, P = 4.0 × 10-12, OR = 16.7), and a frameshift mutation, 69 
rs532464664 (p.Val330GlyfsTer106) in the CHADL gene that associates through a recessive 70 
mode of inheritance (homozygote frequency = 0.15%, P = 4.5 × 10-18 and OR = 7.71). 71 
c.1141G>C heterozygotes and individuals homozygous for rs532464664 have their hip 72 
replacement operation 13.5 years and 4.9 years younger than others (P = 0.0020 and P = 73 
0.0026), respectively. We show that the full-length CHADL transcript is expressed in cartilage. 74 
Furthermore, the premature stop codon introduced by the CHADL frameshift mutation results 75 
in nonsense mediated decay of the mutated transcripts.   76 
 77 
  78 
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Osteoarthritis (OA) is a highly heterogeneous disease, or a set of disorders with a great impact 79 
on the quality of life. OA is a disease of the entire joint, affecting cartilage, synovium, 80 
subchondral bone, ligaments and the joint capsule1. Total hip replacement (THR) is a treatment 81 
for severe OA of the hip, indicated by severe pain and reduced mobility, although radiographic 82 
changes in these subjects may vary. Genome-wide association studies (GWAS) of hip OA have 83 
reported a number of common sequence variants, all conferring small to moderate effects2-8. 84 
Here, we report on a GWAS yielding two rare sequence variants that associate with end-stage 85 
hip OA; THR. 86 
We included 4,657 Icelanders who have undergone THR because of OA as cases and 207,514 87 
individuals as population controls in the GWAS. The sequence variants included in the analyses 88 
were identified through whole-genome sequencing of 8,453 Icelanders, and subsequently 89 
imputed into those 150,656 who had been chip-typed and their first and second degree 90 
relatives. We then tested for association between THR and these sequence variants; 31.6 million 91 
variants under the multiplicative model, and 19.2 million variants under the recessive model. 92 
Under the multiplicative model, two variants met the thresholds of genome-wide significance 93 
that accounts for prior probability of impact of the variants9 (Methods, Supplementary Fig. 1a); 94 
a rare missense variant in the cartilage oligomeric matrix protein (COMP) gene at 19p13.11 95 
(hg38 position chr19:18,787,521, P = 3.1 × 10-9, OR = 10.4, allelic frequency 0.033%) and a 96 
frameshift variant in the chondroadherin-like (CHADL) gene at 22q13.2 (rs532464664, P = 1.5 × 97 
10-7, OR = 1.37, allelic frequency 3.92%). Variants at other loci did not reach genome-wide 98 
significance. Nominal association (P < 0.05) was observed for 9 of the 12 previously reported hip 99 
OA loci (Supplementary Table 1). 100 
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Because the mutation in COMP is very rare in our dataset it was validated by direct genotyping. 101 
The directly typed genotypes were then used to re-impute the variant into the OA cases and 102 
controls (Supplementary Note). This resulted in improved imputation (imputation information 103 
1.00 versus 0.95) and stronger association (P = 4.0 × 10-12, OR = 16.7, allelic frequency 0.026% or 104 
in 1 in 1900 persons in our study population). (Table 1, Supplementary Table 2). 105 
The variant in the COMP gene is a C to G transversion at hg38 position chr19:18,787,521 106 
(NM_000095.2:c.1141G>C, NP_000086.2:p.Asp369His), resulting in a replacement of asparagine 107 
with histidine at amino acid position 369 of the COMP protein (Supplementary Fig. 2). The 108 
COMP protein is an important functional component of the extracellular matrix of the 109 
cartilage10 and serum level of the protein is an indicator of cartilage breakdown. As such it is 110 
being evaluated as a prognostic marker for incidence of knee and hip OA11.  Missense mutations 111 
in the COMP protein are known to cause two skeletal dysplasias; pseudoachondroplasia 112 
(PSACH)12 and multiple epiphyseal dysplasia (MED)13 (Supplementary Note, Supplementary Fig. 113 
2), conditions characterized by severe to mild short limb dwarfism with early onset OA because 114 
of dysplasia under a dominant mode of inheritance. None of the c.1141G>C heterozygotes (n = 115 
117) have been diagnosed with MED or other dysplasia, and are of normal height 116 
(Supplementary Fig. 3, Supplementary Table 3). Their disease is indistinguishable from other 117 
primary hip OA14 (Supplementary Note, Supplementary Fig. 4). The COMP c.1141G>C 118 
heterozygous individuals form a genealogical cluster that spans seven generations and track the 119 
mutation to a founder born around 1840 (Supplementary Figs. 5, 6). The c.1141G>C mutation 120 
also associates with radiographic OA without THR; P = 8.1 × 10-20 and OR = 29.6 when THR and 121 
radiographic OA are analyzed together (5,109 cases / 222,460 controls). The mutation also 122 
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associates with knee, spine and hand OA, albeit with weaker effects (Supplementary Table 2). 123 
Furthermore, we found that the c.1141G>C heterozygotes are 13.5 years younger than others to 124 
have their hip replaced, or 54.5 years old, on average, versus 68.0 years old (P = 0.0020, Fig. 1a, 125 
1b, Supplementary Table 4). Heterozygous carriers of the mutation in the control group are also 126 
younger than the THR heterozygotes (Supplementary Table 5).The variant is not reported in the 127 
Exome Aggregation Consortium (ExAC) Browser15, the Genome Aggregation Database 128 
(gnomAD)15, or in the Exome Variant Server (EVS) (http://evs.gs.washington.edu/EVS/v.0.0.17) 129 
and was not found in samples of European origin (n = 12,980) whom we directly genotyped. 130 
Thus, the variant likely represents a single mutational event that predisposes to OA at the mild 131 
end of the COMP gene mutations spectrum and follows a dominant mode of inheritance. See 132 
Supplementary Note for more data on the c.1141G>C (p.Asp369His) variant. 133 
 134 
The association of the rs532464664 frameshift variant in the CHADL gene with THR is much 135 
stronger under the recessive than the multiplicative model (Supplementary Fig. 1b), reaching P 136 
= 4.5 × 10-18 and OR = 7.7 (Table 1). Furthermore, the associated risk in the multiplicative model 137 
can be fully explained by the contribution of the homozygous individuals. The frameshift variant 138 
is an 8 base pair (bp) insert, rs532464664, in the third exon of the gene 139 
(NM_138481.1:c.988_989insGGCGCGCG, NP_612490.1:p.Val330GlyfsTer106, allele frequency 140 
3.92%, homozygous frequency 0.15%), that puts the protein out of frame at amino acid 330, out 141 
of the 762 full length protein, and introduces a stop codon 106 amino acids downstream of the 142 
frameshift (Supplementary Fig. 7). Under the recessive model eight additional variants at the 143 
CHADL locus, all highly correlated with the frameshift mutation, associate with THR. None of 144 
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these variants associate significantly after accounting for the effect of the homozygous state of 145 
the rs532464664[insGGCGCGCG] allele (Fig. 2, Supplementary Fig. 8, Supplementary Table 6).  146 
Similar to the variant in COMP, we found that the rs532464664 mutation affects the age at THR; 147 
homozygous individuals were, on average, 4.9 years younger than others when they had their 148 
hip replacement (P = 0.0073; Fig. 1c, 1d, Supplementary Table 7). Homozygous individuals in 149 
the control group are also younger than those in the THR group (Supplementary Table 5). 150 
We re-examined all available radiographs of the hip for 784 of the homozygous individuals and 151 
demonstrated that their disease is indistinguishable from other primary hip OA (Supplementary 152 
Note, Supplementary Fig. 9). 153 
The rs532464664 is in a region with very high GC content (80%) that is badly covered by the 154 
standard Illumina TruSeq sequencing technique. This may explain why the mutation is not 155 
reported in the ExAC15, gnomAD15, or EVS databases (Supplementary Table 8, Supplementary 156 
Fig. 10). However, since a large fraction of our sequencing data is generated with either a 157 
Illumina PCR free TruSeq or Illumina TruSeq Nano methods that perform better than the 158 
standard TruSeq method in GC-rich regions, we are able to reliably call rs532464664 159 
(Supplementary Fig. 11). 160 
We directly genotyped the rs532464664 variant in ten different populations, four of which 161 
included THR samples (Methods).  Rs532464664 is present in all the populations except the 162 
Koreans, with a frequency range from 0.13% to 2.55% (Supplementary Table 9).  163 
We found five homozygous individuals who had undergone THR in UK samples (NTHR = 2,711), 164 
one in Danish samples (NTHR = 660), one in Norwegian samples (NTHR = 138) and none in Swedish 165 
samples (NTHR = 376). Due to the low frequency of homozygous individuals in these samples 166 
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(0.041% to 0.065%) we lack statistical power to assess association with THR. However, we 167 
observed, like in Iceland, a similar, although non-significant (P = 0.081), trend of THR at a 168 
younger age for the homozygous UK individuals; the UK homozygotes were 59 years old 169 
compared to 67 years (Fig. 1e). 170 
 171 
We explored mRNA expression of the CHADL gene in RNA sequencing data of white blood cells 172 
(n = 2,528), adipose tissue (n = 655) and cartilage (n = 16) and identified two types of CHADL 173 
transcripts; a full-length transcript in cartilage and a shorter non-coding transcript, with start 174 
site in exon 3 downstream of rs532464664, in adipose tissue (Supplementary Fig. 12). In 175 
adipose tissue rs532464664 is correlated with increased expression of this shorter transcript (P 176 
= 1.4 × 10-23, 54% increase in expression per allele carried) (Supplementary Fig. 13).  177 
We further explored CHADL mRNA expression profile in 23 tissues by quantitative PCR (qPCR) 178 
(Methods) and found that highest expression of full-length CHADL is in the spinal cord and 179 
brain, followed by cartilage tissue (Supplementary Fig. 14).  Specific qPCR analysis of joint tissue 180 
samples showed highest expression of full-length CHADL in joint cartilage (Fig. 3a) and in 181 
cultured chondrocytes (Fig. 3b, 3c). The high expression of the CHADL gene in cartilage is in line 182 
with expression of the mouse homolog, Chadl16.  183 
Since no carriers of rs532464664 were among the RNA sequenced cartilage samples we could 184 
not determine whether the premature stop codon introduced by rs532464664 induced 185 
nonsense mediated decay (NMD), a process responsible for eliminating aberrant mRNA 186 
transcripts with premature stop codons17. To investigate potential NMD effect of the premature 187 
stop codon we utilized an in vitro reporter system for evaluation of NMD (Methods, 188 
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Supplementary Fig. 15). Similar systems have been used successfully to monitor the status of 189 
the NMD machinery in cells18,19. Strikingly, the expression of the reporter protein was reduced 190 
when fused to a gene fragment harboring rs532464664[insGGCGCGCG] in comparison to the 191 
wild type allele and this reduction was partially reverted with the NMD inhibitors, indicating 192 
that rs532464664 induces NMD of the aberrant mRNA (Supplementary Fig. 15).  Chadl 193 
knockdown in the mouse chondrogenic cell-line (ATCD5) demonstrated that lack of Chadl 194 
enhances the differentiation of the cell line and deposition of collagen II and aggrecan. This links 195 
the protein with the formation of extracellular matrix of the cartilage and suggests that Chadl 196 
may play a negative regulatory role in the cartilage. 197 
 198 
In summary, we report a rare missense variant in the COMP gene and a recessive frameshift 199 
mutation in the CHADL gene that associates strongly with OA hip replacement. Both variants 200 
confer substantial risk of THR; 16.7 and 7.7, respectively. These odds ratios are substantially 201 
higher than for the previously reported common OA variants, which range from 1.1 to 1.797, 202 
and may represent Mendelian forms of OA. Furthermore, both those homozygous for 203 
rs532464664 (p.Val330GlyfsTer106) and those heterozygous for the c.1141G>C (p.Asp369His) 204 
mutation in COMP have hip replacement at a younger age than others. Although the COMP 205 
mutation is specific to the Icelandic population, the frameshift mutation in CHADL is widespread 206 
in populations of European and Middle-Eastern descent and found in lower frequency in East-207 
Asians, suggesting that the mutation occurred a long time ago. It is one of very few variants that 208 
associate under the recessive model in GWAS of a common disease.  209 
 210 
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FIGURE LEGENDS 279 
 280 
Figure 1.    Age at total hip replacement by COMP variant genotype and CHADL variant 281 
genotype 282 
a) Age at THR by COMP variant c.1141G>C (g.chr19:18,787,521) genotype.  283 
b) Kaplan-Meier estimator curves for THR according to genotype status of c.1141G>C in COMP. 284 
Hazard ratio for heterozygotes vs. non-carriers is 9.46 (95% CI: 5.09 – 17.61). 285 
c) Age at THR by CHADL variant rs532464664 genotype.  Mann-Whitney tests for age at 286 
operation give P = 0.0025 for homozygotes vs. non-carriers, P = 0.35 for heterozygotes vs. non-287 
carriers and P = 0.0080 for homozygotes vs. heterozygotes. 288 
d) Kaplan-Meier curves for THR according to genotype status of rs532464664 in CHADL. Hazard 289 
ratio for homozygotes versus the two other genotypes is 8.20 (95% CI: 5.93 – 11.34) 290 
e) Age at THR by CHADL rs532464664 variant genotype for the UK arcOGEN cohort.   291 
 292 
In the Icelandic samples all individuals were chip-typed and the genotypes imputed, in the UK 293 
samples the genotypes were derived from direct genotyping. Mann-Whitney tests were used to 294 
estimate differences in age at operation. The P values are two-sided. Hazard ratios were 295 
calculated using the Cox proportional hazard model, adjusting for gender and year of birth. The 296 
box-plots in a), c), and e) show the age at THR operation by genotype; the bottom and top of 297 
the boxes correspond to the 25th (Q1) and 75th (Q3) percentiles, the line inside the box the 298 
median age and the whiskers are located at Q1 - 1.5 IQR and Q3 + 1.5 IQR, respectively (where 299 
IQR is the interquartile range = Q3 - Q1). 300 
 301 
302 
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Figure 2. Regional association plot for the 22q13.2 CHADL locus. 303 
a) P-values (−log10) of variant association with THR under a recessive model in the Icelandic 304 
samples are plotted against their NCBI Build 38 positions at the 22q13.2 locus as black circles. 305 
Red crosses represent association with THR after adjusting for the homozygous state for 306 
rs532464664 (variant indicated by a vertical broken line). Known genes in the region are shown 307 
underneath the plot, taken from the UCSC genes track in the UCSC Genome Browser.  308 
b) A zoom-in on the CHADL gene (RefSeq accession: NM_138481). 309 
 310 
 311 
 312 
 313 
Figure 3. CHADL gene expression in human joint tissues, primary cells and mesenchymal 314 
stem cell (MSC) differentiation. 315 
a) CHADL gene expression in cartilage (Cart) from non-OA neck of femur (NOF) fractures (n = 7), 316 
in cartilage (n = 7) and trabecular bone (n = 6) from OA hips and in cartilage (n = 19), trabecular 317 
bone (n = 10), synovium (Syn; n = 10) and fat pad (FP; n = 9) from OA knees.  318 
b) CHADL gene expression in cultured human articular chondrocytes (HACs; n = 7) and human 319 
osteoblasts (HOBs; n = 4) from OA knees.  320 
Data is expressed as mean ± standard error of the mean. P-values are two-sided. 321 
c) CHADL gene expression in undifferentiated healthy MSCs and after 14 days of differentiation 322 
into chondrocytes (Chondro), adipocytes (Adipo) and osteoblasts (Osteo).  323 
  324 
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Table 1.   Association of c.1141G>C in COMP (0.026%) and homozygous state of rs532464664 (0.15%) in CHADL with osteoarthritis 325 
in Iceland 326 
 327 
   
c.1141G>C in COMP 
(multiplicative model)a  
rs532464664 in CHADL 
(recessive model)b 
Phenotype Ncases / Ncontrols OR 95% CI P-value OR 95% CI P-value 
Total hip replacement 4,657 / 207,514 16.7 7.5, 36.9 4.0 × 10-12  7.71 4.86, 12.25 4.5 × 10
-18 
Total knee replacement 3,289 / 170,001     1.14   0.24, 5.50 0.87 2.35 1.17,   4.72 0.016 
Hand osteoarthritis 8,514 / 235,277       3.48   1.49, 8.11 0.0039   1.81 1.08,   3.03 0.023 
 328 
 329 
Phenotypes of associations are shown with the number of cases and control.  330 
a Association results under a multiplicative model for the missense variant c.1141G>C in the COMP gene (hg38 genomic position 331 
chr19:18,787,521, NM_000095.2:c.1141G>C, NP_000086.2:p.Asp369His). The frequency of the g.chr19:18,787,521[G] allele is 332 
0.026% in Iceland. The odds-ratio is given with respect to the minor allele G of the variant. P values are two-sided. 333 
b Association results under a recessive model for the 8 bp insertion allele CGCGCGCC at hg38 position chr22:41,238,083 in exon 3 of 334 
the CHADL gene (NM_138481.1:c.988_989insGGCGCGCG, NP_612490.1:p.Val330GlyfsTer106). The 8 bp insertion allele has 3.92% 335 
allele frequency in Iceland. The odds-ratio is given for the homozygous genotype of the minor allele insCGCGCGCC. P values are two-336 
sided. 337 
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Online Methods 338 
STUDY POPULATIONS 339 
Iceland:  The information on total hip replacements comes from a national Icelandic hip or knee 340 
arthroplasty registry20,21 and from Landspitali University Hospital electronic health records. The 341 
registry was generated with computer-aided search of hospital records on all patients who had 342 
undergone total joint replacements for primary osteoarthritis of the hip or knee from any of the 343 
6 orthopedic clinics in Iceland during the period from 1972 up to, and including, 2008. A clinician 344 
reviewed all patient records in 3 of the 6 hospitals and determined that the proportion of 345 
correct diagnosis was greater than 98%. Additionally, computer-aided search of joint 346 
replacement operations was performed in the Landspitali University Hospital’s electronic health 347 
records up to, and including, 2015. Diagnoses such as hip fracture, rheumatoid arthritis and 348 
secondary causes of osteoarthritis, such as Perthes disease, hip dysplasia and slipped 349 
epiphysiolysis, were excluded. The total knee replacements were drawn from the same registry 350 
and from the Landspitali University Hospital. Those who had ruptured their anterior crucial 351 
ligament were also excluded from the knee replacements list. Because not all patient records 352 
could be reviewed for confirmation of diagnosis, we only included patients 40 years and older at 353 
the time of hip replacement in the genome-wide association scan. However, for the analysis of 354 
age at hip replacement and the survival analysis we also included individuals who had surgery at 355 
an earlier age. The average age, height and weight by gender of those undergoing THR and 356 
controls are shown in Supplementary Table 10. 357 
Hand osteoarthritis patients were drawn from a database of 8,500 hand osteoarthritis patients 358 
that was initiated in 197222. Participants were considered to have hand osteoarthritis if they had 359 
either definite finger osteoarthritis or definite thumb osteoarthritis, or both. Finger 360 
osteoarthritis was defined as definite bony swellings on at least one distal interphalangeal joint 361 
on each hand. Thumb osteoarthritis was defined as having definite squaring and/or dislocation 362 
of the first carpometacarpal joint. 363 
Information on radiographic hip osteoarthritis was drawn from the Landspitali University 364 
Hospital, the total joint replacement registry and the hand osteoarthritis database.  365 
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All participants gave informed consent and the study was approved by the Data Protection 366 
Commission of Iceland and the National Bioethics Committee of Iceland. 367 
 368 
Other populations:  The Swedish samples were from the Swedish Malmo Diet and Cancer 369 
(MDC) study of men and women living in the city of Malmo in Sweden who were born between 370 
1923 and 1945 (men) or between 1923 and 1950 (women). The Danish samples are 371 
postmenopausal women in the age range 55–86 years, taking part in the Prospective 372 
Epidemiological Risk Factor (PERF study)23. The Norwegian samples consisted of patients from 373 
memory clinics with cognitive symptoms or dementia and controls recruited from orthopaedic 374 
clinics, all enrolled in the DemGene project24. The Dutch study subjects are from the “Nijmegen 375 
Biomedical Study”25. The samples from the UK included individuals visiting the Leicester Royal 376 
Infirmary, Leicester and the Royal Hallamshire Hospital, Sheffield, and individuals from three 377 
primary care practices located in the same geographical area26, and the arcOGEN sample 378 
collection of individuals who had undergone total joint replacement at nine different centers in 379 
the UK8. The Spanish individuals are part of a larger collection of control samples of European 380 
descent obtained from individuals who had attended the University Hospital in Zaragoza, Spain 381 
between November 2001 and May 2007. All controls are of self-reported European descent27. 382 
The samples from USA are from subjects taking part in a study of Polycystic Ovary Syndrome at 383 
Massachusetts General Hospital, Boston, USA28. Only individuals of European descent were 384 
included in this study. The Iranian samples are part of the Tehran Lipid and Glucose Study (TLGS) 385 
cohort29. The Chinese Hong Kong samples are comprised of two samples of different sex, the Mr 386 
OS and Ms OS studies, aged 65 years and above30. The Korean samples are postmenopausal 387 
women who visited the Osteoporosis Clinic of Asan Medical Center (AMC, Seoul, Korea)31. All 388 
participants in these studies provided informed consent and we obtained approval from all 389 
institutional review board to carry out the study. 390 
 391 
GENOTYPING, IMPUTATION AND ASSOCIATION ANALYSIS:  Genotyping and imputation 392 
methods and the association analysis method in the Icelandic samples were essentially as 393 
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previously described32 with some modifications that are described here. In short, we sequenced 394 
the whole genomes of 8,453 Icelanders using Illumina technology to a mean depth of at least 395 
10X (median 32X) (Supplementary Fig. 16). The sequencing was performed using the following 396 
three different library preparation methods and sequencing instruments from Illumina: (i) 397 
standard TruSeq DNA library preparation method; Illumina GAIIx and/or HiSeq 2000 sequencers; 398 
(ii) TruSeq DNA PCR-free library preparation method; Illumina HiSeq 2500 sequencers; and (iii) 399 
TruSeq Nano DNA library preparation method; Illumina HiSeq X sequencers (see Supplementary 400 
Note for a detailed description of the sequencing methods). SNPs and indels were identified and 401 
their genotypes called using joint calling with the Genome Analysis Toolkit HaplotypeCaller 402 
(GATK version 3.3.0)33. Genotype calls were improved by using information about haplotype 403 
sharing, taking advantage of the fact that all the sequenced individuals had also been chip-typed 404 
and long range phased. The sequence variants identified in the 8,453 sequenced Icelanders 405 
were then imputed into 150,656 Icelanders who had been genotyped with various Illumina SNP 406 
chips and their genotypes phased using long-range phasing34,35. Using genealogic information, 407 
the sequence variants were imputed into 294,212 un-typed relatives of the chip-typed to 408 
further increase the sample size for association analysis and increased the power to detect 409 
associations. Individuals who have undergone total hip replacements and controls were either 410 
chip-typed individuals (Naffected = 3,110, Ncontrols = 99,911) or first/second degree relatives of chip-411 
typed individuals that were not chip-typed themselves (Naffected=1,547, Ncontrols=107,603). The 412 
number of affected males was 2,163 and affected females was 2,494. Association testing for 413 
case-control analysis was performed using logistic regression, adjusting for gender, age and 414 
county. A total of 31.6 million variants were used in the association analysis under a 415 
multiplicative model. For the recessive analysis, the number of tested variants for which we had 416 
homozygotes for the minor allele was 19.2 million. All of the variants that were tested had 417 
imputation information over 0.8. 418 
To account for relatedness and stratification within the case and control sample sets, we applied 419 
the method of genomic control36. The inflation factor λg in the χ2 statistic in each genome-wide 420 
analysis was estimated on the basis of a subset of about 300,000 common variants, and P-values 421 
were adjusted by dividing the corresponding χ2 values by this factor. For the traits reported 422 
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here, the estimated inflation factors for the multiplicative (recessive) models were 1.29 (1.11) 423 
for total hip replacement, 1.16 (1.06) for total knee replacement, 1.32 (1.13) for hand OA and 424 
1.04 (1.00) for radiographic hip OA without hip replacement.  425 
We used the weighted Holm-Bonferroni method37 to allocate familywise error rate of 0.05 426 
equally between three annotation-based classes of sequence variants 9. For the multiplicative 427 
model, this yielded significance thresholds of 1.7 × 10-6 for loss-of-function (LoF) variants 428 
(including stop-gained, frameshift, splice acceptor or donor; N=9,989), 9.8 × 10-8 for missense, 429 
splice-region variants and in-frame indels (N=170,692), and 5.3 × 10-10 for other (non-coding) 430 
variants (N=31,421,778); the significance thresholds and number of variants tested under the 431 
recessive model were 2.5 × 10-6 (N=6,799), 1.3 × 10-7 (N=124,475) and 8.7 × 10-10 432 
(N=19,083,372), respectively. 433 
 434 
SINGLE VARIANT GENOTYPING: The c.1141G>C (g.chr19:18787521) variant in COMP was 435 
genotyped using the Centaurus (Nanogen) platform38. The 8 bp CHADL frameshift insert was 436 
genotyped using a PCR based method with the primers shown in Supplementary Table 11.  An 437 
internal size standard was added to the resulting PCR products and the fragments were 438 
separated on an Applied Biosystems model 3730 sequencer and then detected and called using 439 
in-house Allele Caller software.  440 
 441 
RNA SEQUENCING ANALYSES: 442 
Preparation of Poly-A cDNA sequencing libraries. Total RNA was isolated from PaxGene (Qiagen) 443 
blood tubes. The quality and quantity of isolated total RNA samples was assessed using the 444 
Total RNA 6000 Nano chip for the Agilent 2100 Bioanalyzer. cDNA libraries derived from Poly-A 445 
mRNA were generated using Illumina‘s TruSeq RNA Sample Prep Kit. Briefly, Poly-A mRNA was 446 
isolated from total RNA samples (1–4 μg input) using hybridizaton to Poly-T beads. The Poly-A 447 
mRNA was fragmented at 94°C, and first-strand cDNA was prepared using random hexamers 448 
and the SuperScript II reverse transcriptase (Invitrogen). Following second-strand cDNA 449 
synthesis, end repair, addition of a single A base, adaptor ligation, AMPure bead purification, 450 
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and PCR amplification; the resulting cDNA was measured on a Bioanalyzer using the DNA 1000 451 
Lab Chip. 452 
Sequencing. Samples were clustered on to flowcells using Illumina‘s cBot and the TruSeq PE 453 
cluster kits v2. Paired-end sequencing was performed with either GAIIx instruments using the 454 
TruSeq SBS kits v5 from Illumina or HiSeq 2000 instruments using TruSeq v3 flowcells/SBS kits; 455 
read lengths were 2×125 cycles. 456 
Read alignment. RNA sequencing reads were aligned to Homo sapiens Build 38 with TopHat 457 
version 2.0.12 with a supplied set of known transcripts in GTF format (RefSeq hg38; Homo 458 
sapiens, NCBI,build 38). TopHat was configured such that it attempts first to align reads to the 459 
provided transcriptome then, for reads that do not map fully to the transcriptome, it attempts 460 
to map them onto the genome. Unmapped reads and reads aligning within 20 kb flanking region 461 
of CHADL were extracted and re-aligned using the Burrows-Wheeler Aligner (BWA-MEM 0.7.10) 462 
to the CHADL RefSeq transcript NM_138481.1 with and without the 8 bp insertion (HGVSc for 463 
mutated transcript: NM_138481.1:c.981_988dupGGCGCGCG); low quality reads were filtered 464 
out with Sickle 35 (version 1.33) prior to realignment and the minimum alignment score 80 was 465 
used in BWA-MEM. 466 
RNA expression. TopHat aligned reads were used for quantifying CHADL expression for 467 
association testing for rs532464664. HTSeq-count39 was used to count fragments aligning to 468 
genes. Count values were normalized with Trimmed Mean of M-values40 method implemented 469 
with edgeR (v. 3.12.1) Bioconductor package.  470 
Expression association. Linear regression assuming additive genetic effect was performed on 471 
log-transformed RNA expression estimates. The following covariates were used to correct for 472 
technical differences in the RNA experiments: average fragment length, exonic rate, number of 473 
genes detected, number of mapped read pairs, number of alternative alignments and 474 
percentage of reads originating from coding bases. 475 
 476 
 477 
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QUANTITATIVE PCR TISSUE PANEL EXPRESSION ANALYSES: 478 
cDNA was synthesized using the High capacity cDNA reverse transcriptase kit (Applied 479 
Biosystems Inc.) on total RNA from several tissues (Cartilage tissue from DV biologics cat# SKU: 480 
AM009-R and the rest from Clonetech). Expression assays for the CHADL gene were designed 481 
using Roche universal probe library (Prod#: 04683633001), one for exon 2-3 junction and 482 
another for exon 3-4 junction (Supplementary Table 11). Real-time PCR was carried out 483 
according to manufacturer’s recommendations on an ABI Prism 7900HT Sequence Detection 484 
System. Human GUSB (Applied Biosystems) was used to test the quality of the cDNA and correct 485 
for slight variance in input amount. Reactions were performed in duplicate, representative 486 
results are shown in Supplementary Fig. 14. 487 
 488 
QUANTITATIVE PCR EXPRESSION ANALYSES OF JOINT TISSUES ISOLATED FROM TOTAL JOINT 489 
REPLACEMENTS: 490 
Patients and samples:  Joint tissue samples were obtained from patients with primary 491 
osteoarthritis (OA) or with neck of femur (NOF) fracture undergoing total knee (OA patients) or 492 
total hip (OA and NOF patients) replacement surgery at the Newcastle upon Tyne NHS 493 
Foundation Trust hospitals. The Newcastle and North Tyneside Research Ethics Committee 494 
granted ethical approval for the collection of the samples (REC reference number 14/NE/1212), 495 
with each donor providing informed consent. NOF patients showed no signs or symptoms of hip 496 
OA, and their cartilage was macroscopically intact and with no lesions. 497 
Samples were stored at 4oC in Hank’s Balanced Salt Solution (HBSS) supplemented with 498 
Penicillin-Streptomycin and Nyastatin. Articular cartilage (distal from the lesion for the OA 499 
patients), trabecular bone, synovium and fat pad were obtained from the different patients 500 
when available.  501 
The tissue samples that were to be used for RNA extraction were snap-frozen after collection, 502 
with the fresh trabecular bone samples being chopped in TRIzol® reagent (Ambion). These 503 
samples were then stored at -80oC. 504 
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Cell culture:  Cartilage from OA knees was processed for human articular chondrocyte (HAC) 505 
isolation. Cartilage was digested with 1 mg/ml Hyaluronidase at 37oC for 15 min followed by 2.5 506 
mg/ml trypsin at 37oC for 30 min. Then, cartilage was incubated with 2.5 mg/ml collagenase at 507 
35.5oC overnight. Isolated chondrocytes were plated and cultured in DMEM containing 10% FBS 508 
and Penicillin-Streptomycin for 10 days. 509 
Human osteoblasts (HOB) were obtained by culturing bone pieces from OA knees in culture 510 
dishes with DMEM containing 20% heat-inactivated FBS and Penicillin-Streptomycin until the 511 
cells reached confluence. 512 
Human mesenchymal stem cells (MSCs) from a healthy donor were purchased from Lonza, UK. 513 
MSCs were differentiated into chondrocytes for 14 days as previously described 41.  For 514 
osteogenic differentiation, cells were seeded at 1.3 x 104/cm2 and cultured in DMEM containing 515 
10% FBS, Penicillin-Streptomycin, 0.1 µM dexamethasone, 10 mM β-glycerophosphate and 50 516 
µM ascorbic acid for 14 days. Adipogenesis was achieved by two cycles of adipogenic induction 517 
for 3 days (DMEM supplemented with 10% FBS, 1 μM dexamethasone, 10 μg/ml insulin, 0.5 mM 518 
isobutylmethylxanthine, 60 μM indomethacin, 2 μM Rosiglitazone and 20 nM IGF-1) followed by 519 
4 days in maintenance medium (DMEM supplemented with 10% FBS and 10 μg/ml insulin). 520 
RNA isolation and cDNA synthesis:  RNA from synovium, fat pad and cultured cells was isolated 521 
using E.Z.N.A.® DNA/RNA Isolation Kit (Omega Bio-tek) following manufacturer’s protocol.  522 
Trabecular bone RNA was isolated using TRIzol® reagent according to manufacturer’s protocol, 523 
and RNA from cartilage was extracted using TRIzol® reagent followed by RNeasy Mini Kit 524 
(Qiagen) as previously described 42. 525 
1 µg of RNA was used for cDNA synthesis using SuperScript™ First-Strand Synthesis System 526 
(Invitrogen) after digestion at 37oC for 30 min with TURBO™ DNase (Ambion), following 527 
manufacturer’s protocol. 528 
Gene expression analysis by quantitative real-time PCR:  Gene expression was determined 529 
using an ABI PRISM 7900HT Fast Real Time PCR System (Applied Biosystems). All reactions were 530 
performed in triplicate, and CHADL mRNA levels were normalised to GAPDH, HPRT1 and 18S 531 
and expressed using 2−∆Ct. Primers and probes used are given in Supplementary Table 11.  532 
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Statistical analysis was performed using Kruskal-Wallis test, followed by Dunns post test, or 533 
Mann-Whitney test when appropriate. All analyses were performed using Prism v6 software 534 
(GraphPad Software Inc). P (two sided) < 0.05 was considered statistically significant. 535 
 536 
NONSENSE MEDIATED DECAY REPORTER ASSAY 537 
Construction of NMD reporter system.  The HBB and CHADL gene fragments were amplified 538 
using Phusion High-Fidelity polymerase (NEB) from human genomic DNA derived from human 539 
peripheral blood. CHADL gene fragments were obtained from a carrier and non-carrier of the 8 540 
bp insert, whereas a premature translation termination codon was introduced at the start of the 541 
sequence of HBB using the HBB_R_STOP that created a target for NMD. The gene fragments 542 
correspond to chr11:5,246,722-5,248,029 (UCSC Genome Browser on Human Feb. 2009 543 
GRCh37/hg19 Assembly) and chr22:41,632,489-41,634,216 (UCSC Genome Browser on Human 544 
Feb. 2009 GRCh37/hg19 Assembly) for HBB and CHADL respectively. The primers used for PCR 545 
are given in Supplementary Table 11. All sequences were verified by Sanger sequencing using 546 
standard methodology. The pmirGLO (Promega E133A) vector was used as a backbone for the 547 
NMD reporters. In order to create fused gene sequences, the stop codon of the luc2 was 548 
removed by using Q5 Site-directed mutagenesis kit (NEB E0554S) with primers show in 549 
Supplementary Table 11. The sequence of the plasmid was verified by Sanger sequencing. Prior 550 
to cloning of gene constructs the vector was linearized with the NheI restriction enzyme (NEB 551 
R0131S). All gene fragments were cloned downstream of the luc2 with a Gibson cloning kit (NEB 552 
M5510A) following manufacturers recommendations creating a fusion protein of luc2 and the 553 
relevant gene fragments. Plasmids were isolated with QIAprep Spin miniprep kit (QIAGEN) and 554 
inserts were verified by Sanger sequencing.  555 
 Luminescence analysis.   Two days prior to transfection, 30,000 HeLa cells (Public Health 556 
England 93021013) were seeded into each well of a 96-well plate in 200µL of DMEM medium 557 
(11995-065, ThermoFisher) supplemented with 10% fetal calf serum (ThermoFisher 10500-064) 558 
and 50 units/mL penicillin and 50 ug/mL streptomycin (ThermoFisher 15070-063). Cells were 559 
incubated overnight at 37°C and 5% CO2 in a humidified incubator. Each well was washed once 560 
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with PBS and 90µL of medium was added to each well without antibiotics and cells were 561 
incubated overnight. For each well, 100ng of plasmid DNA was transfected using Lipofectamine 562 
3000 (ThermoFisher L30000-008). 48 hours post transfection luminescence was measured using 563 
the Dual-Glo Luciferase system (Promega E220) on a Glomax Discover (Promega GM3000). Data 564 
were presented as the luc2/hRluc-neo ratio calculated for each well. For inhibitor experiments, 565 
cells were cultured as described and then treated with 10mM caffeine for the last 24 hours prior 566 
to luminescence measurements or the last 8 hours with 20µM wortmaninn. 567 
 568 
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